The one-time leader of the DNA analysis market – valued at $6 billion in 2021 – is now worth less than $100 million, a 99 ...
Wojcicki and New Mountain have offered to acquire all of 23andMe's outstanding shares in cash for $2.53 per share, or an ...
Me CEO Anne Wojcicki and New Mountain Capital propose $2.53/share buyout to take company private, valuing it at $74.7M after ...
Discover the rise and dramatic fall of 23andMe, once a $6 billion genetics pioneer. From revolutionising consumer DNA testing to facing privacy breaches and market shifts, OxStu explores how trust, ...
Company Notes Continued Concerns Regarding Liquidity and Consideration of Potential Ways to Address Operational and Financial Challenges SUNNYVALE, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE ...
23andMe is in need of cash and weighing a sale of the company. The DNA-testing company said Tuesday that it is exploring strategic alternatives, including a business combination and the sale of ...
February is Cancer Prevention Month, and oftentimes when we think about breast cancer, we think about females, but not males.
Anne Wojcicki’s decision to take 23andMe private with the backing of New Mountain Capital marks a crucial moment in the ...
23andMe CEO Anne Wojcicki and New Mountain Capital have submitted a proposal to take the company private. They are offering to buy all outstanding shares in cash for $2.53 per share, or an equity ...
We will need to raise additional liquidity to fund our operations and financial commitments. 23andMe ended December 31, 2024 with cash and cash equivalents of $79.4 million, compared to $126.6 ...